MarginProbe® System U.S. Post-Approval Study
Purpose
The study objective is to determine the MarginProbe® System's diagnostic accuracy at the margin level and impact on Positive Margin* Presence originating from the Main ex-vivo lumpectomy specimen after the initial lumpectomy surgery. *A positive margin is defined in this study as a margin microscopically measured and reported in the histology report to have cancer within 1 mm or less of the inked surface
Condition
- Breast Cancer
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Women histologically diagnosed with carcinoma of the breast - Women with non-palpable malignant lesions, requiring image guided localization. - Undergoing lumpectomy (partial mastectomy) procedure - Age 18 years or more - Signed ICF
Exclusion Criteria
- Multi-centric disease (histologically diagnosed cancer in two different quadrants of the breast) - Bilateral disease (diagnosed cancer in both breasts) - Neo-adjuvant systemic therapy - Previous radiation in the operated breast - Prior surgery in the same site in the breast - Woman histologically diagnosed by an open biopsy procedure - Implants in the operated breast - Pregnancy - Lactation - Participating in any other investigational study for either drug or device which could influence collection of valid data under this study - Patients for whom complete cavity shaving is planned (sites where this is the routine practice of the investigator will also be excluded from participation in the study)
Study Design
- Phase
- N/A
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Supportive Care
- Masking
- Single (Participant)
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Other SOC + Device |
The surgeon will perform routine standard of care lumpectomy with adjunctive MarginProbe device use on the main ex-vivo lumpectomy specimen. |
|
Other SOC + Additional Inspection |
The surgeon will perform routine standard of care lumpectomy with additional inspection on the main ex-vivo lumpectomy specimen. |
|
More Details
- Status
- Unknown status
- Sponsor
- Dune Medical Devices
Study Contact
Detailed Description
This is a prospective, multicenter, randomized (1:1), double arm, controlled study, in which subjects undergoing breast excision (lumpectomy) for carcinoma of the breast will be randomized to either standard of care with additional inspection ('SOC + Additional inspection' arm) or standard of care with MarginProbe as an adjunct ('SOC + Device' arm). The MarginProbe is an adjunctive diagnostic tool for identification of cancerous tissue at the margins (≤ 1mm) of the main ex-vivo lumpectomy specimen following primary excision. It will be used by the surgeon during lumpectomy procedures only in patients randomized to the "Device+SOC" arm. Randomization will take place following the excision of the main ex-vivo lumpectomy specimen.